Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study

Michael A. Bolognese, Christence Stubbe Teglbjærg, Jose R. Zanchetta, Kurt Lippuner, Michael R. McClung, Maria Luisa Brandi, Arne Høiseth, P. Lakatos, Alfred H. Moffett, Roman S. Lorenc, Andrea Wang, Cesar Libanati

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1. mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3% at 36 months were observed in 90% of denosumab-treated subjects at the lumbar spine and 74% at the total hip, and gains more than 6% occurred in 77% and 38%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36. mo with important gains observed in most subjects.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalJournal of Clinical Densitometry
Volume16
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Photon Absorptiometry
Bone Density
Hip
Spine
Femur
Placebos
Femur Neck
Skeleton
Osteoporosis
Denosumab
Therapeutics

Keywords

  • Bone mineral density
  • Denosumab
  • DXA
  • Osteoporosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bolognese, M. A., Teglbjærg, C. S., Zanchetta, J. R., Lippuner, K., McClung, M. R., Brandi, M. L., ... Libanati, C. (2013). Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study. Journal of Clinical Densitometry, 16(2), 147-153. https://doi.org/10.1016/j.jocd.2012.02.006

Denosumab significantly increases DXA BMD at both trabecular and cortical sites : Results from the FREEDOM study. / Bolognese, Michael A.; Teglbjærg, Christence Stubbe; Zanchetta, Jose R.; Lippuner, Kurt; McClung, Michael R.; Brandi, Maria Luisa; Høiseth, Arne; Lakatos, P.; Moffett, Alfred H.; Lorenc, Roman S.; Wang, Andrea; Libanati, Cesar.

In: Journal of Clinical Densitometry, Vol. 16, No. 2, 04.2013, p. 147-153.

Research output: Contribution to journalArticle

Bolognese, MA, Teglbjærg, CS, Zanchetta, JR, Lippuner, K, McClung, MR, Brandi, ML, Høiseth, A, Lakatos, P, Moffett, AH, Lorenc, RS, Wang, A & Libanati, C 2013, 'Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study', Journal of Clinical Densitometry, vol. 16, no. 2, pp. 147-153. https://doi.org/10.1016/j.jocd.2012.02.006
Bolognese, Michael A. ; Teglbjærg, Christence Stubbe ; Zanchetta, Jose R. ; Lippuner, Kurt ; McClung, Michael R. ; Brandi, Maria Luisa ; Høiseth, Arne ; Lakatos, P. ; Moffett, Alfred H. ; Lorenc, Roman S. ; Wang, Andrea ; Libanati, Cesar. / Denosumab significantly increases DXA BMD at both trabecular and cortical sites : Results from the FREEDOM study. In: Journal of Clinical Densitometry. 2013 ; Vol. 16, No. 2. pp. 147-153.
@article{6aaf9b2c5cef47fb9a1938ed8898774d,
title = "Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study",
abstract = "Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1. mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3{\%} at 36 months were observed in 90{\%} of denosumab-treated subjects at the lumbar spine and 74{\%} at the total hip, and gains more than 6{\%} occurred in 77{\%} and 38{\%}, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36. mo with important gains observed in most subjects.",
keywords = "Bone mineral density, Denosumab, DXA, Osteoporosis",
author = "Bolognese, {Michael A.} and Teglbj{\ae}rg, {Christence Stubbe} and Zanchetta, {Jose R.} and Kurt Lippuner and McClung, {Michael R.} and Brandi, {Maria Luisa} and Arne H{\o}iseth and P. Lakatos and Moffett, {Alfred H.} and Lorenc, {Roman S.} and Andrea Wang and Cesar Libanati",
year = "2013",
month = "4",
doi = "10.1016/j.jocd.2012.02.006",
language = "English",
volume = "16",
pages = "147--153",
journal = "Journal of Clinical Densitometry",
issn = "1094-6950",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Denosumab significantly increases DXA BMD at both trabecular and cortical sites

T2 - Results from the FREEDOM study

AU - Bolognese, Michael A.

AU - Teglbjærg, Christence Stubbe

AU - Zanchetta, Jose R.

AU - Lippuner, Kurt

AU - McClung, Michael R.

AU - Brandi, Maria Luisa

AU - Høiseth, Arne

AU - Lakatos, P.

AU - Moffett, Alfred H.

AU - Lorenc, Roman S.

AU - Wang, Andrea

AU - Libanati, Cesar

PY - 2013/4

Y1 - 2013/4

N2 - Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1. mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3% at 36 months were observed in 90% of denosumab-treated subjects at the lumbar spine and 74% at the total hip, and gains more than 6% occurred in 77% and 38%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36. mo with important gains observed in most subjects.

AB - Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated. Significant BMD improvements were observed as early as 1. mo at the lumbar spine, total hip, and trochanter (all p<0.005 vs placebo and baseline). BMD increased progressively at the lumbar spine, total hip, femoral neck, trochanter, 1/3 radius, and total body from baseline to months 12, 24, and 36 (all p<0.005 vs placebo and baseline). BMD gains above the least significant change of more than 3% at 36 months were observed in 90% of denosumab-treated subjects at the lumbar spine and 74% at the total hip, and gains more than 6% occurred in 77% and 38%, respectively. In conclusion, denosumab treatment resulted in significant, early, and continued BMD increases at both trabecular and cortical sites throughout the skeleton over 36. mo with important gains observed in most subjects.

KW - Bone mineral density

KW - Denosumab

KW - DXA

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84877074012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877074012&partnerID=8YFLogxK

U2 - 10.1016/j.jocd.2012.02.006

DO - 10.1016/j.jocd.2012.02.006

M3 - Article

C2 - 22521543

AN - SCOPUS:84877074012

VL - 16

SP - 147

EP - 153

JO - Journal of Clinical Densitometry

JF - Journal of Clinical Densitometry

SN - 1094-6950

IS - 2

ER -